ArticleJTO clinical and research reports2026
Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer.
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Primary thymic adenocarcinomas are a rare subtype of thymic carcinoma, which share morphologic and immunohistochemical features with gastrointestinal cancers. The immunologic features of thymic adenocarcinoma remain poorly understood, and optimal treatment strategies have not been established. Methods: In this single-institution retrospective study, we identified seven patients with enteric-type thymic adenocarcinoma. Clinical characteristics, histopathology, and molecular profiles were analyzed. Comprehensive immune profiling was conducted using peripheral blood mononuclear cells (PBMCs) and archival tumor tissue. The PBMC immune profiles were compared with those of non-adenocarcinoma thymic epithelial tumors and with samples obtained from healthy donors. Results: Enteric-type thymic adenocarcinomas exhibit aggressive clinical behavior and respond poorly to systemic therapy, including immune checkpoint inhibitors. Genomic analyses revealed frequent TP53 mutations, a marker of poor prognosis for thymic epithelial tumors. Immune analyses in PBMCs revealed higher levels of effector T-cell subsets, including CD4 Conclusions: Enteric-type thymic adenocarcinomas are immunologically cold tumors that are enriched in peripheral immune markers reflective of cell proliferation and angiogenesis. The immunologic profile appears distinct from other thymic epithelial tumors and provides a potential explanation for the aggressive nature of this disease. If validated in other studies, these findings can potentially inform the development of optimal systemic therapies for this rare variant of thymic carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.